The portfolio maintains a cost advantage over competitors, priced within the second-lowest fee quintile among peers.
Fidelity Select Pharmaceuticals Port FPHAX
- NAV / 1-Day Return 27.98 / +0.04 %
- Total Assets 1.1 Bil
-
Adj. Expense Ratio
- Expense Ratio 0.760%
- Distribution Fee Level Low
- Share Class Type No Load
- Category Health
- Investment Style Large Growth
- Min. Initial Investment —
- Status Open
- TTM Yield 0.50%
- Turnover 45%
USD | NAV as of Mar 28, 2024 | 1-Day Return as of Mar 28, 2024, 10:12 PM GMT+0
Morningstar’s Analysis FPHAX
Will FPHAX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 70.4
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Eli Lilly and Co | 23.39 | 217.7 Mil | Healthcare |
Novo Nordisk A/S ADR | 14.64 | 136.3 Mil | Healthcare |
AstraZeneca PLC ADR | 8.45 | 78.6 Mil | Healthcare |
Merck & Co Inc | 5.14 | 47.9 Mil | Healthcare |
GSK PLC ADR | 4.83 | 45.0 Mil | Healthcare |
UCB SA | 3.51 | 32.7 Mil | Healthcare |
Gilead Sciences Inc | 3.12 | 29.0 Mil | Healthcare |
Royalty Pharma PLC Class A | 2.79 | 25.9 Mil | Healthcare |
Merck KGaA | 2.27 | 21.1 Mil | Healthcare |
Moderna Inc | 2.23 | 20.8 Mil | Healthcare |